Sutro Biopharma, Inc.
STRO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001382101
No open-market purchases or sales by Sutro Biopharma, Inc. insiders were filed in the last 90 days; 100 institutions reported holding it in 13F filings for Q2 2026, worth $545.7M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Sutro Biopharma, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 109 | 114 | +5 |
| Shares | 55.9M | 55.6M | −246.4K (−0.4%) |
| Value | $194.3M | $238.7M | +$44.4M (+22.9%) |
New holders (20)
Institutions that held Sutro Biopharma, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Aquilo Capital Management, LLC | 420,649 | $1.80M | 1.27% |
| Two Sigma Investments, LP | 323,192 | $1.39M | 0.00% |
| Opaleye Management Inc. | 301,491 | $1.29M | 0.35% |
| Propel Bio Management, LLC | 195,000 | $836.5K | 0.69% |
| Bridgeway Capital Management, LLC | 170,200 | $730.2K | 0.02% |
| Exome Asset Management LLC | 153,600 | $658.9K | 0.65% |
| Cubist Systematic Strategies, LLC | 76,126 | $326.6K | 0.00% |
| Walleye Capital LLC | 73,271 | $314.3K | 0.00% |
| Standard Life Aberdeen plc | 69,389 | $297.7K | 0.00% |
| Engineers Gate Manager LP | 56,580 | $242.7K | 0.01% |
| Aristides Capital LLC | 50,476 | $216.5K | 0.11% |
| Kennedy Capital Management, Inc. | 29,845 | $128.0K | 0.00% |
| Susquehanna Portfolio Strategies, LLC | 26,668 | $114.4K | 0.00% |
| Virtu Financial LLC | 16,766 | $72.0K | 0.01% |
| Dynamic Technology Lab Private Ltd | 13,899 | $60.0K | 0.01% |
| Squarepoint Ops LLC | 13,903 | $59.6K | 0.00% |
| Quantbot Technologies LP | 3,312 | $14.2K | 0.00% |
| Point72 Middle East FZE | 1,798 | $7.71K | 0.00% |
| Cape Investment Advisory, Inc. | 1,000 | $4.29K | 0.00% |
| Simplex Trading, LLC | 187 | $0 | 0.00% |
Sold out (15)
Institutions that held Sutro Biopharma, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Holocene Advisors, LP | 2,132,873 | $7.40M |
| Frazier Life Sciences Management, L.P. | 780,000 | $2.71M |
| Susquehanna Fundamental Investments, LLC | 71,113 | $246.8K |
| Putnam Investments LLC | 68,393 | $237.3K |
| Los Angeles Capital Management LLC | 68,324 | $237.1K |
| Gsa Capital Partners LLP | 67,754 | $235.0K |
| Mirae Asset Global Investments Co., Ltd. | 45,441 | $157.7K |
| Virtus Investment Advisers, Inc. | 28,274 | $98.1K |
| Trexquant Investment LP | 20,421 | $70.9K |
| Allspring Global Investments Holdings, LLC | 17,319 | $60.1K |
| ProShare Advisors LLC | 11,770 | $40.8K |
| Manchester Capital Management LLC | 10,561 | $36.6K |
| Qube Research & Technologies Ltd | 4,953 | $17.2K |
| China Universal Asset Management Co., Ltd. | 1,546 | $5.37K |
| Daiwa Securities Group Inc. | 158 | $1.00K |